[8-K] Evolv Technologies Holdings, Inc. Reports Material Event

Rhea-AI Filing Summary

Form 8-K filing (30 Jul 2025) discloses two material items from VYNE Therapeutics Inc. (Nasdaq: VYNE).

• Item 8.01 – Other Events: The company issued a press release titled “VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo” and posted an investor presentation. Both are furnished as Exhibits 99.1 and 99.2.
• Item 2.02 – Preliminary cash position: Although Q2-25 results are not finalized, management expects to report approximately $39.6 million in cash, cash equivalents and investments at 30 Jun 2025. This figure is unaudited and subject to change once condensed consolidated financial statements are completed.

No additional financial metrics, guidance or transactional details were provided. The filing notes that the company’s independent auditor has not performed any procedures on the preliminary cash number.

Insights

Financial Analyst

TL;DR: 8-K announces phase-2b topline release and $39.6 m cash; limited quantitative detail, impact neutral.

The filing mainly alerts investors to forthcoming clinical data rather than providing results themselves. The preliminary $39.6 million cash balance implies roughly three to four quarters of runway based on recent burn rates, but the figure is unaudited and could shift. With no efficacy or safety statistics, investors cannot yet assess the potential value inflection from repibresib gel. Overall, disclosure is routine and informational; market impact hinges on the separate press release once data are reviewed.

Biotech Industry Specialist

TL;DR: Pipeline milestone flagged; real significance depends on absent efficacy data—overall disclosure neutral.

Announcing topline Phase 2b results signals continued progress in vitiligo, a sizable unmet need. However, without response rates, durability or safety figures, it is impossible to gauge regulatory or commercial prospects. The provided cash snapshot suggests VYNE can fund near-term R&D, but does not materially change risk profile. Investors should examine the posted presentation for data before revising valuations.

false 0001805385 0001805385 2025-07-29 2025-07-29 0001805385 us-gaap:CommonClassAMember 2025-07-29 2025-07-29 0001805385 us-gaap:WarrantMember 2025-07-29 2025-07-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): July 29, 2025

Evolv Technologies Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39417		84-4473840
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

500 Totten Pond Road, 4th Floor
Waltham, Massachusetts   02451

(Address of principal executive offices) (Zip Code)

781 374 8100

(Registrant’s telephone number, including area code)

N/A 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A common stock, par value $0.0001 per share		EVLV		The Nasdaq Stock Market
Warrants to purchase one share of Class A common stock		EVLVW		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01 Entry into a Credit Agreement.

On July 29, 2025, Evolv Technologies, Inc. (the ”Borrower”), a direct, wholly-owned subsidiary of Evolv Technologies Holdings, Inc. (“the Company”), entered into the Credit, Security and Guaranty Agreement (the “Credit Agreement”), by and among the Borrower, the Company, MidCap Financial Trust, as agent and term loan service and the other lenders party thereto, that provides for an initial $30 million term loan facility, $30 million delayed draw facility (available for drawdown during the two-year period following the closing date), and a $15 million revolving facility, each with a term of five years (collectively, the “senior secured credit facilities”). The proceeds of any borrowings under the senior secured credit facilities will be used for general corporate purposes.

The Credit Agreement contains customary affirmative and negative covenants, including, among other things, limitations on the Company and its subsidiaries with respect to liens, incurrence of indebtedness, certain fundamental changes, restricted payments, investments and transactions with affiliates, in each case, subject to customary exceptions. The senior secured credit facilities are guaranteed by the Company, and in the future, may be guaranteed by certain material subsidiaries. The senior secured credit facilities are secured by a first lien on substantially all of the assets of the Borrower and the Company.

Under the Credit Agreement, the Borrower is also required to comply with a minimum annual recurring revenue covenant, a minimum earnings before interest, taxes, depreciation, and amortization (“EBITDA”) covenant that takes effect on the second anniversary of the closing date, and a minimum liquidity covenant that would cease to apply following the resolution of certain litigation and regulatory matters.

Borrowings under the senior secured credit facilities bear interest at a fluctuating rate per annum equal to, at the Borrower’s option, the base rate or Term Secured Overnight Financing Rate (“Term SOFR”), in each case, plus an applicable margin calculated depending on EBITDA, ranging from 5.00% to 5.25% (or 4.00% to 4.25% for base rate borrowings). At closing, the applicable margin on Term SOFR loans is 5.25%.

The foregoing description of the Credit Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Credit Agreement, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are filed as part of this report:

Exhibit No.		Description
10.1		Credit, Security and Guaranty Agreement, dated as of July 29, 2025, among Evolv Technologies Inc., Evolv Technologies Holdings, Inc., lenders party thereto and MidCap Financial Trust as agent and term loan servicer and the other lenders party thereto from time to time.
99.1		Press Release.
104		Cover Page Interactive Data file (formatted as Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 30, 2025

	EVOLV TECHNOLOGIES HOLDINGS, INC.
	By:	/s/ George C. Kutsor
	Name:	George C. Kutsor
	Title:	Chief Financial Officer

FAQ

What event did VYNE (VYNE) report in its 8-K dated July 30, 2025?

The company announced it had released topline Phase 2b data for repibresib gel in nonsegmental vitiligo and posted a related presentation.

How much cash does VYNE expect to report for Q2 2025?

VYNE preliminarily expects approximately $39.6 million in cash, cash equivalents and investments as of June 30, 2025.

Is the cash figure audited?

No. The amount is unaudited, subject to change, and has not been reviewed by the company’s independent public accounting firm.

Where can investors find the detailed Phase 2b data?

The data are included in the presentation filed as Exhibit 99.2 and available on VYNE’s website.

Were any other financial results disclosed in the filing?

No. Aside from the preliminary cash balance, the 8-K provides no additional financial metrics or guidance.